Needleless Vaccine

Zydus Life has clarified that there has been no official communication regarding permission for the two-dose regimen of the needle-less ZyCoV-D vaccine. ZyCov-D, an indigenous DNA-plasmid-based vaccine against Sars-Cov-2, was given emergency use authorisation for restricted use last year by the Central Drugs Standard Control Organisation (CDSCO). The three-dose vaccine was found to be over 66% effective in the third phase clinical trial.